Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial.Martinez-de-Albeniz I, Bottomley C, Lucinde R, Kaniu MW, Badaud S, Mutahi M, Mwalekwa L, Ragab S, Twi-Yeboah L, Berkley JA, Hamaluba M, Karani A, Shangala J, Otiende M, Gardiner E, Mugo D, Smith PG, Tabu C, Were F, Goldblatt D, Scott JAG, Gallagher KE
Vaccine, (2026). 73:128186
Pneumococcal carriage prevalence, serotype distribution, and vaccine coverage in Ethiopia 12Â years after pneumococcal vaccine introduction.Bizuayehu HY, Kebede Y, Deressa M, Solomon E, Marami D, Karani A, Gardiner E, Dessie Y, Scott JAG, Gallagher KE
Vaccine, (2025). 64:127762
The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.Lucinde RK, Karia B, Ouma N, Amadi D, Nyundo C, Mataza C, Nyaguara A, Scott JAG, Gallagher KE, Kagucia E
Vaccine, (2023). 41:666-675
Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.Lucinde RK, Ong'ayo G, Houlihan C, Bottomley C, Goldblatt D, Scott JAG, Gallagher KE
Vaccine, (2021). 39:5095-5105
